IHI Unveils New Human Factors Certification and Safer Together Program at Patient Safety Congress
IHI Unveils New Human Factors Certification and Safer Together Program at Patient Safety Congress The 2025 IHI Patient Safety Congress officially launched today, gathering healthcare professionals, patient safety advocates, and learners from across the globe to advance safer and more…
NeoGenomics Acquires Pathline to Expand Oncology Testing in the Northeast
NeoGenomics Acquires Pathline to Expand Oncology Testing in the Northeast NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, has announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. This acquisition significantly enhances NeoGenomics’…
GoodRx Report Highlights Gender Divide in Prescription Spending
GoodRx Report Highlights Gender Divide in Prescription Spending GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., has released a new report titled The Prescription Drug Gender Divide. The report reveals that women face a significantly higher…
Eric Peacock Appointed Chief Patient Officer of Swoop
Eric Peacock Appointed Chief Patient Officer of Swoop Swoop, a leader in AI-powered, data-driven, and privacy-compliant omnichannel healthcare marketing, has announced the appointment of Eric Peacock as Chief Patient Officer. This move underscores the company’s commitment to enhancing patient outcomes…
Align Technology Launches AI-Powered Align X-ray Insights in EU and UK
Align Technology Launches AI-Powered Align X-ray Insights in EU and UK Align Technology, Inc., a global leader in medical devices known for its Invisalign® clear aligner system, iTero™ intraoral scanners, and exocad™ CAD/CAM software, has announced the launch of Align…
First Real-World Study Shows GenAI-Powered Mental Health Treatment Outperforms Standard Care
First Real-World Study Shows GenAI-Powered Mental Health Treatment Outperforms Standard Care The first real-world study on the use of Generative Artificial Intelligence (GenAI) in mental health treatment across multiple clinical sites has been published in JMIR Publications. The research revealed…
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease
Ventus Therapeutics Doses First Patient in Phase 2a Trial of VENT-02 for Parkinson’s Disease Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for immunological, inflammatory, and neurological disorders, has announced the dosing of the first patient…
Study Confirms HER2DX® Assay’s Impact on Early-Stage HER2-Positive Breast Cancer Decisions
Study Confirms HER2DX® Assay’s Impact on Early-Stage HER2-Positive Breast Cancer Decisions REVEAL GENOMICS®, an innovative biotech company based in Barcelona, is excited to announce the publication of a groundbreaking study showcasing the clinical impact of HER2DX®, its genomic diagnostic test…
Incyte Presents Phase 3 Results of Ruxolitinib Cream for Prurigo Nodularis at AAD 2025
Incyte Presents Phase 3 Results of Ruxolitinib Cream for Prurigo Nodularis at AAD 2025 Incyte (Nasdaq: INCY) today announced the results of its pivotal Phase 3 TRuE-PN clinical trial program, which includes the TRuE-PN1 and TRuE-PN2 studies. These trials evaluated…
Synseer Launches HealthBuds™ to Revolutionize Health
Synseer Launches HealthBuds™ to Revolutionize Health Synseer, an innovative health and wellness company, is set to debut HealthBuds™ at the SXSW 2025 event in Austin, Texas on March 10. These next-generation earbuds are designed to do more than just provide…
Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu’s Superiority in Psoriatic Arthritis
Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Showing Sotyktu’s Superiority in Psoriatic Arthritis Bristol Myers Squibb (NYSE:BMY) today announced positive results from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib)…
VTAMA® Phase 3 Data Shows Sustained Low Atopic Dermatitis Activity After Treatment-Free Interval
VTAMA® Phase 3 Data Shows Sustained Low Atopic Dermatitis Activity After Treatment-Free Interval Organon (NYSE: OGN), a global healthcare company specializing in women’s health, announced the results of a new analysis from the Phase 3 ADORING 3 open-label, long-term extension…